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ABSTRACT:
Chronic myeloid leukemia (CML) is initiated from the BCR-ABL-expressing leukemia 
stem cells (LSCs). These LSCs are highly resistant to BCR-ABL kinase inhibitors, imatinib, 
dasantinib and nilotinib, and methods for eradication of LSCs are still not available. It 
is critical to identify genes that play roles in survival and proliferation of LSCs. We 
recently discovered that the tumor suppressor gene Pten is downregulated in LSCs 
of CML mice. By genetic deletion or overexpression of Pten, we confirmed that Pten 
functions as a tumor suppressor in LSCs of CML, consistent with the role of Pten in LSCs 
of acute myeloid leukemia (AML) and progenitor cells of T-ALL progenitors. Functional 
enhancement of the Pten pathway provides a therapeutic strategy for targeting LSCs. 
INTRODUCTION
The human Philadelphia chromosome (Ph) is present 
in over 95% of CML cases [1], and arises from a recip-
rocal translocation between chromosome 9 and 22, result-
ing in the formation of the chimeric BCR-ABL oncogene. 
BCR-ABL encodes a constitutively activated, oncogenic 
tyrosine kinase [2]. The BCR-ABL kinase inhibitor ima-
tinib  induces  a  complete  hematologic  and  cytogenetic 
response in the majority of CML patients [3], but is unable 
to  completely  eradicate  BCR-ABL-expressing  leukemic 
cells, suggesting that LSCs are not eliminated. Over time, 
patients can become drug resistant and develop progressive 
disease despite continued treatment [4-6]. 
LSCs in many types of hematologic malignancies are 
believed  to  be  a  cell  population  required  for  initiating 
and  sustaining  growth  of  the  leukemia  [7-13].  In  CML 
patients, bone marrow CD34+Lin- cells, in which normal 
hematopoietic  stem  cells  (HSCs)  reside,  are  thought  to 
contain  CML  stem  cells  and  be  responsible  for  disease 
initiation, progression and resistance to imatinib [14, 15]. 
Several clinical reports have confirmed that disease relapse 
occurred  in  CML  patients  who  had  achieved  complete 
molecular  response  after  imtainib  treatment  but  discon-
tinued the therapy [16, 17]. These results indicate that for 
some reasons, LSCs find ways to survive the treatment by 
BCR-ABL kinase inhibitors.
LSCs in CML are insensitive to inhibition by BCR-
ABL kinase inhibitors
A study showed that a quiescent cell population in LSCs 
(Lin-CD34+) from CML patients was resistant to imatinib 
[14], suggesting that LSCs are insensitive to a BCR-ABL 
kinase inhibitor. To support this idea, two second-genera-
tion BCR-ABL kinase inhibitors, dasatinib and nilotinib, 
were used to treat LSCs in vitro. Dasatinib is a dual Src/
BCR-ABL kinase inhibitor and exhibits a much greater 
potency than imatinib [18]. Although dasatinib led to sig-
nificant inhibition of BCR-ABL kinase activity, the most 
primitive quiescent CML LSCs (Lin-CD34+CD38-) were 
resistant  to  dasatinib  treatment  [19].  Similarly,  nilotinib 
with a potency which is 20-fold higher than imatinib could 
not induce apoptosis of LSCs [20]. In  CML mice treated 
with imatinib or dasatinib, we showed that although these 
two drugs dramatically prolonged survival of CML mice, 
all diseased mice eventually died of CML due to the fail-
ure of imatinib and dasatinib to eradicate LSCs [21]. New 
genes with therapeutic potential are needed to be identified 
for targeting LSCs.157
Role of Pten in LSCs
To identify genes that are differentially regulated by 
BCR-ABL in LSCs, we compared the global gene expres-
sion between normal hematopoietic stem cells (HSCs) and 
LSCs by conducting a DNA microarray analysis [22]. We 
found that Pten is significantly downregulated by BCR-
ABL [23]. Because Pten is often deleted or inactivated in 
many human cancers, including glioblastoma [24], endo-
metrial carcinoma [25], and lymphoid malignancies [26], 
we decided to test whether Pten also functions as a tumor 
suppressor in survival of LSCs and CML development. We 
first assessed whether genetic deletion of Pten facilitates 
CML  development  by  using  Pten  conditional  knockout 
mice (Ptenfl/fl) as donor mice in our retroviral transduction/
transplantation mouse model of CML. In so doing, bone 
marrow cells of Ptenfl/fl mice were transduced with BCR-
ABL-iCre-GFP retrovirus or BCR-ABL-GFP retrovirus (as 
a control), followed by transplantation of the transduced 
cells into lethal irradiated recipient mice. Mice receiving 
donor cells transduced with BCR-ABL-iCre-GFP devel-
oped  CML  much  faster  that  mice  receiving  donor  cells 
transduced with BCR-ABL-GFP, with a higher percentage 
of myeloid leukemia cells and more severe infiltration of 
leukemia cells in the lungs. To confirm the role of Pten in 
CML, we examined whether overexpression of Pten causes 
a delay of CML development. We induced CML in mice 
with BCR-ABL-Pten-GFP or BCR-ABL-GFP, and found 
that CML development was significantly slower when Pten 
was overexpressed. Pten overexpression caused cell cycle 
arrest and increased apoptosis of leukemia cells. Next, we 
examined whether Pten suppresses LSCs. To do so, we 
compared the percentages of LSCs with and without ectop-
ically expressed Pten, and found that Pten overexpression 
caused a decrease in the percentage of bone marrow LSCs, 
suggesting that Pten has an inhibitory effect on LSCs. To 
support this observation, we sorted LSCs from mice with 
CML induced by BCR-ABL-Pten-GFP or BCR-ABL-GFP, 
followed by transplantation of these LSCs into secondary 
recipients. We found that Pten overexpression reduced the 
ability of LSCs to induce CML [27]. Because mTOR is 
hyperactived or upregulated when Pten is mutated or dete-
leted in human cancers [28],  we treated LSCs from CML 
mice or human CML cell line K562 in vitro with rapamy-
cin, a mTOR inhibitor, and found that rapamycin induced 
apoptosis of these cells, suggesting that a blockade of the 
mTOR pathway may help to inhibit LSCs and CML devel-
opment. 
Potential mechanisms of Pten in LSCs
Although Pten is intensively studied in solid tumors and 
T cell-acute lymphoid leukemia (T-ALL) [29-32], little is 
known about Pten in CML until we show that Pten inhibits 
LSCs and CML development [27]. This result is supported 
by a clinical study which compared globe gene expression 
between normal CD34+ HSCs and CD34+ subsets from 
six patients with chronic phase CML. Besides the changes 
of gene expression for several adhesion molecules, tran-
scription factors, cell cycle and stem cell fate regulators, 
Pten was also downregulated [33]. Another study showed 
that the gene expression profiles of mononuclear cells from 
CML patients who achieved complete cytogenetic response 
after imatinib treatment also indicated the Pten downregu-
lation [34]. However, the mechanisms of Pten regulation of 
LSC function in CML need to be investigated. We noticed 
that the level of phosphorlated-Akt (p-Akt) was signifi-
cantly lower in leukemia cells from CML mice when Pten 
was overexpressed [27], suggesting that p-Akt is a critical 
player of the Pten pathway. This idea is supported by our 
finding that induction of B-cell acute lymphoblastic leuke-
mia (B-ALL) in mice was largely compromised when Akt1 
was absent, as shown by the prolonged survival of recipi-
ents of BCR-ABL transduced Akt-deficient bone marrow 
cells mice [27]. The involvement of Akt1 in cancer has 
been shown in endometrium tumor, prostate cancer, thy-
roid tumor, adrenal medulla tumors and intestinal polyps 
in Pten+/- mice [35]. However, the roles of the Akt family 
members (Akt1, Akt2 and Akt3) in CML need to be stud-
ied further in the future. We have shown that expression 
of the Alox5 gene is upregulated by BCR-ABL in CML 
LSCs [36], and it has been reported that Alox5 activates 
p-Akt through oxidation and inhibition of Pten [37]. The 
functional relationship between Pten and Alox5 needs to 
be studied.
  When Pten is specifically deleted in mouse hematopoi-
etic cells, the mice develop acute myeloid leukemia (AML) 
and acute lymphoid leukemia, and all mice died within 4 
weeks [38, 39]. LSCs in these mice are highly enriched in 
Lin-Sca1+cKit+Flk2-CD48- population [38]. A blockade 
of differentiation from LT-HSC (Lin-Sca1+cKit+Flk2-) to 
ST-HSC (Lin-Sca1+cKit+Flk2+) was also found in Pten 
deficient mice, causing an eventual exhaustion of LT-HSC 
[39]. Increased percentage of S+G2M dividing HSCs was 
observed in Pten deficient mice, indicating that Pten func-
tions as a molecular switch governing the G0-G1 transition 
between the quiescent and activated states of LT-HSCs to 
maintain normal HSCs pool [39]. The role of Pten in cell 
cycle control is consistent with our result that Pten expres-
sion induces cell cycle arrest in BCR-ABL expressing leu-
kemia cells [27]. In addition, cyclin D1 is a well known 
target of the PI3K-Akt pathway [40], maintaining cells at 
G1 stage in preparation for G1/S phase transition. In Pten 
deficient AML mice, a high number of cyclin D1-express-
ing cells were detected in bone marrow, suggesting that 
cyclin D1 is downstream of Pten in cell cycle regulation of 
HSCs. Thus, the role of cyclin D1 in cell cycle regulation 
of LSCs in CML requires further investigation. Further-
more, after rapamycin administration, LSCs were depleted 
and  normal  HSCs  restored  in  Pten-deficient AML  mice 
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[39],  indicating  that  Pten  maintains  normal  HSCs  pool 
and suppresses LSCs through mTOR. It has been reported 
that PML (promyelocytic leukemia protein) plays a role in 
normal HSCs and BCR-ABL transduced quiescent LSCs, 
facilitating leukemia initiation and maintenance [41]. Pml 
deficiency promoted transition of LSCs from quiescent to 
activated stage and Pml-/- LSCs finally failed to initiate 
CML disease contrary to wild type LSCs after serial trans-
plantation. As PML is a repressor of mTOR, inhibition of 
mTOR with rapamycin restored Pml-/- HSCs and the long-
term reconstitution functions of LSCs. Another Pten condi-
tional deletion mouse model demonstrated that Pten partial 
deletion in mouse fetal liver HSCs and their differentiated 
progeny  led  to  a  myeloidprliferative  disorder,  followed 
by actue T-lymphoblastic leukemia (T-ALL) [42]. In this 
study, the Pten deficient Lin-c-KitmidCD3+ population was 
shown to be the T-ALL LSCs through a serial transplanta-
tion assay. Interestingly, ablation of one allele of β-catenin 
significantly delayed the occurrence of acute leukemia. We 
and others have also shown that β-catenin plays a key role 
in maintaining LSCs in CML [43, 44] and AML [45]. 
Taken together, these results allow us to draw a picture 
connecting Pten with other key pathways involved in sur-
vival and proliferation of LSCs, including β-catenin, p53, 
Alox5, PI3K/Akt/mTOR pathways (Figure 1). These path-
ways are disturbed in CML, AML and other malignancies, 
and targeting of the pathways may be beneficial to patients.
CONFLICT OF INTEREST
The authors declare no competing financial interest.
ACKNOWLEDGEMENTS
This work was supported by the grants from the Leu-
kemia & Lymphoma Society and the National Institute of 
Health (R01-CA122142, R01-CA114199) to S.L. S.L. is a 
Scholar of the Leukemia & Lymphoma Society.
REFERENCES 
1.  Westbrook  CA,  Hooberman  AL,  Spino  C,  Dodge  RK, 
Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer 
C, Bloomfield CD. Clinical significance of the BCR-ABL 
fusion gene in adult acute lymphoblastic leukemia: a Cancer 
and Leukemia Group B Study (8762). Blood 1992; 80:2983-
90.
2.  Wong S, Witte ON. The BCR-ABL story: bench to bedside 
and back. Annu Rev Immunol 2004; 22:247-306.
3.  Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford 
JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, 
Sawyers CL. Efficacy and safety of a specific inhibitor of the 
BCR-ABL tyrosine kinase in chronic myeloid leukemia. N 
Engl J Med 2001; 344:1031-7.
4.  Weisberg E, Griffin JD. Mechanism of resistance to the ABL 
tyrosine kinase inhibitor STI571 in BCR/ABL-transformed 
hematopoietic cell lines. Blood 2000; 95:3498-505.
5.  Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, 
Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer 
therapy caused by BCR-ABL gene mutation or amplification. 
Science 2001; 293:876-80.
6.  Shah  NP,  Nicoll  JM,  Nagar  B,  Gorre  ME,  Paquette  RL, 
Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain 
mutations confer polyclonal resistance to the tyrosine kinase 
inhibitor imatinib (STI571) in chronic phase and blast crisis 
chronic myeloid leukemia. Cancer Cell 2002; 2:117-25.
7.  Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, 
Clarke MF. Prospective identification of tumorigenic breast 
cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8.
8.  Pardal R, Clarke MF, Morrison SJ. Applying the principles 
of stem-cell biology to cancer. Nat Rev Cancer 2003; 3:895-
902.
9.  Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, 
cancer, and cancer stem cells. Nature 2001; 414:105-11.
10.  Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, 
Squire J, Dirks PB. Identification of a cancer stem cell in 
human brain tumors. Cancer Res 2003; 63:5821-8.
11.  Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl 
J Med 2006; 355:1253-61.
12.  Wang J, Ouyang W, Li J, Wei L, Ma Q, Zhang Z, Tong Q, 
He  J,  Huang  C.  Loss  of  tumor  suppressor  p53  decreases 
PTEN expression and enhances signaling pathways leading 
to activation of activator protein 1 and nuclear factor kappaB 
induced by UV radiation. Cancer Res 2005; 65:6601-11.
13.  Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the 
pathways to aging and cancer. Cell 2008; 132:681-96.
14.  Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, 
Richmond L, Holyoake TL. Primitive, quiescent, Philadel-
Figure 1. Molecular pathways in LSCs of CML. In LSCs, BCR-
ABL activates multiple signaling pathways that are normally acti-
vated by a receptor tyrosine kinase (RTK). In particular, the PI3K 
and  Wnt/  β-catenin  pathways  are  critically  involved.  The  novel 
Alox5 pathway we identified plays a specific role in LSCs but not 
normal HSCs (see the text for detail), and this pathway may inter-
acts with the tumor suppressor gene Pten. The functional relation-
ship between Alox5 and Pten is an important research topic that 
needs to be studied further.
Oncotarget 2010; 1: 156-160 www.impactjournals.com/oncotarget/159
phia-positive stem cells from patients with chronic myeloid 
leukemia  are  insensitive  to  STI571  in  vitro.  Blood  2002; 
99:319-25.
15.  Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, 
Arber DA, Slovak ML, Forman SJ. Persistence of malignant 
hematopoietic progenitors in chronic myelogenous leukemia 
patients in complete cytogenetic remission following ima-
tinib mesylate treatment. Blood 2003; 101:4701-7.
16.  Cortes J, O'Brien S, Kantarjian H. Discontinuation of ima-
tinib  therapy  after  achieving  a  molecular  response.  Blood 
2004; 104:2204-5.
17.  Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek 
O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas 
M, Mahon FX. Imatinib mesylate discontinuation in patients 
with chronic myelogenous leukemia in complete molecular 
remission for more than 2 years. Blood 2007; 109:58-60.
18.  Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. 
Overriding  imatinib  resistance  with  a  novel  ABL  kinase 
inhibitor. Science 2004; 305:399-401.
19.  Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jor-
danides N, Barow M, Mountford JC, Holyoake TL. Dasatinib 
(BMS-354825) targets an earlier progenitor population than 
imatinib in primary CML but does not eliminate the quiescent 
fraction. Blood 2006; 107:4532-9.
20.  Jorgensen  HG, Allan  EK,  Jordanides  NE,  Mountford  JC, 
Holyoake  TL.  Nilotinib  exerts  equipotent  antiproliferative 
effects to imatinib and does not induce apoptosis in CD34+ 
CML cells. Blood 2007; 109:4016-9.
21.  Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. 
Targeting multiple kinase pathways in leukemic progenitors 
and stem cells is essential for improved treatment of Ph+ leu-
kemia in mice. Proc Natl Acad Sci U S A 2006; 103:16870-5.
22.  Chen Y, Li D, Li S. The Alox5 gene is a novel therapeutic 
target in cancer stem cells of chronic myeloid leukemia. Cell 
Cycle 2009; 8:3488-92.
23.  Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin 
AG, Li S. PTEN is a tumor suppressor in CML stem cells 
and  BCR-ABL-induced  leukemias  in  mice.  Blood  2010; 
115:626-35.
24.  Li  J, Yen  C,  Liaw  D,  Podsypanina  K,  Bose  S, Wang  SI, 
Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, 
Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler 
MH, Parsons R. PTEN, a putative protein tyrosine phospha-
tase gene mutated in human brain, breast, and prostate cancer. 
Science 1997; 275:1943-7.
25.  Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, 
Goodfellow PJ. Allelic loss of sequences from the long arm 
of chromosome 10 and replication errors in endometrial can-
cers. Cancer Res 1995; 55:1922-6.
26.  Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jen-
sen K. Alterations of the MMAC1/PTEN gene in lymphoid 
malignancies. Blood 1998; 91:4388-90.
27.  Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, Pak 
R, Read M, Li S. Inhibition of heat shock protein 90 prolongs 
survival  of  mice  with  BCR-ABL-T315I-induced  leukemia 
and suppresses leukemic stem cells. Blood 2007; 110:678-85.
28.  Guertin DA, Sabatini DM. Defining the role of mTOR in 
cancer. Cancer Cell 2007; 12:9-22.
29.  Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abe-
casis  M,  Nowill AE,  Leslie  NR,  Cardoso AA,  Barata  JT. 
PTEN posttranslational inactivation and hyperactivation of 
the PI3K/Akt pathway sustain primary T cell leukemia viabil-
ity. J Clin Invest 2008; 118:3762-74.
30.  Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFi-
ura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, 
Matherly LH. The impact of NOTCH1, FBW7 and PTEN 
mutations on prognosis and downstream signaling in pedi-
atric T-cell acute lymphoblastic leukemia: a report from the 
Children's Oncology Group. Leukemia 2009; 23:1417-25.
31.  Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, 
Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA. Negative 
prognostic impact of PTEN mutation in pediatric T-cell acute 
lymphoblastic leukemia. Leukemia 2010; 24:239-42.
32.  Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena 
L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, 
Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Sil-
verman LB, Hunger SP, Sallan SE, Look AT. High frequency 
of PTEN, PI3K, and AKT abnormalities in T-cell acute lym-
phoblastic leukemia. Blood 2009; 114:647-50.
33.  Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest 
S,  Bruennert  D,  Huenerlituerkoglu  AN,  Stoecklein  NH, 
Singh R, Zerbini LF, Jager M, Kobbe G, Gattermann N, Kro-
nenwett R, Brors B, Haas R. The hematopoietic stem cell in 
chronic phase CML is characterized by a transcriptional pro-
file resembling normal myeloid progenitor cells and reflect-
ing loss of quiescence. Leukemia 2009; 23:892-9.
34.  de Lavallade H, Finetti P, Carbuccia N, Khorashad JS, Char-
bonnier A, Foroni L, Apperley JF, Vey N, Bertucci F, Birn-
baum D, Mozziconacci MJ. A gene expression signature of 
primary resistance to imatinib in chronic myeloid leukemia. 
Leuk Res; 34:254-7.
35.  Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, 
Di Cristofano A, Pandolfi PP, Hay N. The deficiency of Akt1 
is sufficient to suppress tumor development in Pten+/- mice. 
Genes Dev 2006; 20:1569-74.
36.  Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene 
impairs leukemia stem cells and prevents chronic myeloid 
leukemia. Nat Genet 2009; 41:783-92.
37.  Covey TM, Edes K, Fitzpatrick FA. Akt activation by arachi-
donic acid metabolism occurs via oxidation and inactivation 
of PTEN tumor suppressor. Oncogene 2007; 26:5784-92.
38.  Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, 
Wu H, Morrison SJ. Pten dependence distinguishes haema-
topoietic stem cells from leukaemia-initiating cells. Nature 
2006; 441:475-82.
39.  Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, 
Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, Wu 
H, Li L. PTEN maintains haematopoietic stem cells and acts 
in lineage choice and leukaemia prevention. Nature 2006; 
441:518-22.
40.  Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means 
more. Dev Biol 2004; 273:175-84.
41.  Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda 
Y,  Rosenblatt  J, Avigan  DE,  Teruya-Feldstein  J,  Pandolfi  
PP. PML targeting eradicates quiescent leukaemia-initiating 
cells. Nature 2008; 453:1072-8.
Oncotarget 2010; 1: 156-160 www.impactjournals.com/oncotarget/160
42.  Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y, 
Yeh JE, Chen JY, Iruela-Arispe ML, Varella-Garcia M, Wu 
H. Multi-genetic events collaboratively contribute to Pten-
null leukaemia stem-cell formation. Nature 2008; 453:529-
33.
43.  Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for 
survival of leukemic stem cells insensitive to kinase inhibi-
tion in mice with BCR-ABL-induced chronic myeloid leuke-
mia. Leukemia 2009; 23:109-16.
44.  Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, 
Lagoo A, Reya T. Loss of beta-catenin impairs the renewal 
of normal and CML stem cells in vivo. Cancer Cell 2007; 
12:528-41.
45.  Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, 
Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin path-
way is required for the development of leukemia stem cells in 
AML. Science  2010; 327:1650-3.
Oncotarget 2010; 1: 156-160 www.impactjournals.com/oncotarget/